Atea Pharmaceuticals, Inc.
NASDAQ:AVIRBiotechnology
-$0.04 today
- Market cap
- $320.41M
- Beta
- 0.32
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$2.14
Volume 0.34M
Average 0.34M
AVIR Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Atea Pharmaceuticals, Inc.NASDAQ: AVIR
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue dips below year-ago levels
Q1 FY2026 cost of revenue of $104K fell 97.0% year over year, behind the +72.9% change in trailing-twelve-month cost of revenue.
Context
- Cost of revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -97.0% toward the trailing-twelve-month pace of +72.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 83.37M | +18.9% |
| FY2023 | 2023-12-31 | 70.09M | +12.3% |
| FY2022 | 2022-12-31 | 62.39M | -62.7% |
| FY2021 | 2021-12-31 | 167.21M | — |
Cost of Revenue vs competitors
How AVIR compares with its peers on the latest reported figures
- AVIR's LTM Mar 2026 cost of revenue of $40.76M is the highest of the 5 companies compared; the peer median is $621K.
- Its year-over-year change of +72.9% is the highest of 4, against a peer median of -99.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $40.76M | +72.9% | — | — | |
| LTM Mar 2026 | $16.18M | -62.1% | -87.7% | 22.8% | |
| LTM Mar 2026 | $1.21M | — | — | 1.7% | |
| LTM Mar 2026 | $33K | -99.8% | — | 0.0% | |
| LTM Mar 2026 | -$114.78M | -122.6% | -73.4% | 175.2% | |
| Peer median (excluding AVIR) | $621K | -99.8% | -80.5% | 12.3% | |
Competitors are the stored peer set for AVIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 351.37M | 0 | 0 | 0 | 0 |
| Cost of Revenue | 167.21M | 62.39M | 70.09M | 83.37M | 0 |
| Gross Profit | 184.16M | (62.39M) | (70.09M) | (83.37M) | 0 |
| Gross Margin | 52.4% | — | — | — | — |
| Research & Development | 167.21M | 88.84M | 132.84M | 145.4M | 148.02M |
| Selling, General & Admin | 45.79M | 48.71M | 49.92M | 48.85M | 32.86M |
| Operating Expenses | 45.79M | 68.26M | 94.07M | 109.58M | 180.89M |
| Depreciation & Amortization | 29K | 260K | 416K | 416K | 416K |
| EBITDA | 138.62M | (110.84M) | (119.59M) | (131.8M) | (164.1M) |
| EBITDA Margin | 39.5% | — | — | — | — |
| Operating Income | 138.38M | (130.65M) | (164.16M) | (192.95M) | (180.89M) |
| Operating Margin | 39.4% | — | — | — | — |
| Interest Income | 213K | 11.15M | 29.22M | 25.49M | 16.38M |
| Interest Expense | 0 | 11.15M | 0 | 0 | 0 |
| Other Income / Expenses | 213K | 11.15M | 29.22M | 25.49M | 16.38M |
| Income Before Tax | 138.59M | (119.5M) | (134.94M) | (167.46M) | (164.51M) |
| Pre-Tax Margin | 39.4% | — | — | — | — |
| Income Tax Expense | 17.4M | (3.59M) | 1.02M | 925K | (6.16M) |
| Net Income | 121.19M | (115.91M) | (135.96M) | (168.39M) | (158.35M) |
| Net Margin | 34.5% | — | — | — | — |
| EPS (Basic) | 1.46 | (1.39) | (1.63) | (2.00) | (1.94) |
| EPS (Diluted) | 1.37 | (1.39) | (1.63) | (2.00) | (1.94) |
| Weighted Avg Shares | 82.82M | 83.25M | 83.39M | 84.26M | 81.5M |
| Weighted Avg Shares (Diluted) | 88.25M | 83.25M | 83.39M | 84.26M | 81.5M |
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
Intrinsic Alpha fair value
Locked
Current Price
$3.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.